Loading company details...
Beta
Latest Form 4 (Oct 16, 2026): Anatol Kreitzer (Chief Discovery Officer): Sale of 12,248 shares, $96.0K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 16, 2026 | Anatol Kreitzer, Chief Discovery Officer | Sale | 12,248 | $96.0K |
| Oct 16, 2026 | Jonathan Gillis, CAO and Interim CFO | Sale | 10,167 | $82.1K |
| Oct 16, 2026 | James Woodruff Lillie, Chief Scientific Officer | Sale | 11,513 | $93.0K |
| Oct 16, 2026 | Kristopher Hanson, General Counsel | Sale | 9,020 | $72.9K |
| Oct 16, 2026 | Erin Pennock Foff, Chief Medical Officer | Sale | 15,355 | $124.1K |
| Oct 16, 2026 | Christopher A. Kroeger, Chief Executive Officer | Sale | 73,691 | $595.4K |
| Sep 18, 2026 | Kristopher Hanson, General Counsel | Sale | 16,509 | $192.7K |
| Aug 19, 2026 | Anatol Kreitzer, Chief Discovery Officer | Grant/Award | 6,020 | n/a |
| Aug 19, 2026 | Jonathan Gillis, CAO and Interim CFO | Grant/Award | 6,020 | n/a |
| Aug 19, 2026 | James Woodruff Lillie, Chief Scientific Officer | Grant/Award | 7,730 | n/a |